CompanyGraph
Sells a daily HIV pill taken by millions and builds one-of-a-kind cancer treatments grown from each patient's own blood cells.
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is higher than 95% of all stocks globally
- FinancialsAltman Z-Score: safe zone
- Interpretations1 currently firing — 1
What this company is and how it runs — written from structure, not news.
Gilead Sciences sells a daily HIV pill called Biktarvy, where stopping even briefly allows the virus to rebound, so every stable patient becomes a continuous refill — but that stream lasts only as long as the patent on the specific three-drug combination holds, because once it expires, generic manufacturers can copy the active ingredients through standard chemistry. Alongside that, Gilead makes two CAR-T cancer therapies, Yescarta and Tecartus, where each dose starts from a single patient's extracted T-cells, gets genetically modified at a certified facility over three to four weeks, and is returned to that patient alone, meaning no inventory can be built in advance and total annual output is capped by how many certified manufacturing slots exist rather than by how much money is spent. Adding slots requires facility re-certification, a reliable supply of lentiviral vector, and trained staff — none of which can be rushed — so the CAR-T business grows slowly even when demand is there. Both sides share one vulnerability: if the FDA restricts or pulls approval on any major product, the revenue attached to it collapses immediately, because no other drug in Gilead's portfolio treats the same patients through the same mechanism.
How does this company make money?
The company earns money each time a pharmacy dispenses Biktarvy, Descovy, or other HIV pills, at prices negotiated with insurers and pharmacy benefit managers. Each Yescarta or Tecartus treatment brings in more than $400,000 per patient, paid by hospitals or insurers after the personalized dose is delivered. Epclusa, its hepatitis C cure, is sold at different prices depending on whether the country buying it is classified as high-income or low-income.
What makes this company hard to replace?
An HIV patient who has been stable on Biktarvy cannot simply swap to a different pill — switching requires new viral load tests and possibly resistance testing to confirm the alternative drug will work for their specific virus. A patient in the middle of CAR-T treatment cannot switch products at all, because the therapy is built from their own cells and the manufacturing process is already underway. On the hospital side, any treatment center that wants to offer a different CAR-T product has to go through a separate facility certification process and train its staff again for that specific product.
What limits this company?
The CAR-T side of the business can only treat as many patients per year as its certified facilities can physically process. Because each dose starts from one specific patient's cells, nothing can be made in advance, and each batch occupies a manufacturing slot for three to four weeks. Adding more slots requires building new certified facilities, securing more lentiviral vector — the biological tool used to reprogram the T-cells — and training specialized staff. None of that can be rushed beyond what current biology and regulation allow.
What does this company depend on?
The company cannot operate without FDA approval covering its HIV drug combinations and its CAR-T therapies. On the manufacturing side, it needs cGMP-certified facilities where the genetic modification and cell expansion happen, a reliable supply of lentiviral vector used to reprogram patient T-cells, specialized cold-chain logistics companies that transport patient cells without breaking the temperature chain, and suppliers of the active pharmaceutical ingredients bictegravir and tenofovir alafenamide that go into the HIV pills.
Who depends on this company?
HIV patients taking Biktarvy or Descovy would see their viral resistance patterns return if dosing stopped. Oncology treatment centers use Yescarta for patients with relapsed lymphoma, and those treatment protocols would be disrupted if Yescarta became unavailable. Hepatitis C treatment programs in developing countries rely on Epclusa to meet WHO targets for eliminating the disease, and those programs would fall behind if supply or pricing changed.
How does this company scale?
HIV pill manufacturing gets cheaper and easier as volume grows — once the active ingredients are synthesized, production runs on standard pharmaceutical lines that can be expanded with capital. The CAR-T business does not scale the same way. Every patient requires individual cell extraction, a dedicated manufacturing slot, genetic modification, and expansion in a specialized facility. That process cannot be automated beyond what current biotechnology allows, so output grows slowly no matter how much money is spent.
What external forces can significantly affect this company?
WHO hepatitis C elimination programs push governments in developing countries to negotiate lower prices for Epclusa, squeezing margins on that product. U.S. government policy on PrEP — pre-exposure HIV prevention — determines how broadly Descovy is reimbursed, directly affecting how many patients can access it. The Inflation Reduction Act gives Medicare the authority to negotiate HIV drug prices directly, which puts downward pressure on what the company can charge for its highest-revenue pill products in the United States.
Where is this company structurally vulnerable?
If FDA placed a hold on Sunlenca because of a stability failure, a cold-chain contamination event, or a safety signal found after launch, the six-month dosing interval that makes Sunlenca different from every daily oral competitor would be gone. There is no way to quickly reformulate it — any new version would have to go back through clinical trials, which takes years.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Multi-Year Up-Close-Week Share With Profitability And Book-Value Growth
Three observations describe the present configuration: a high share of the trailing three years' weekly closes were higher than the prior week, the company has reported positive net income in each of the last five annual periods, and the book-value-increase-consistency composite over the trailing 5 years is elevated.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.